8-K: Candel Therapeutics Announces Positive Clinical Trial Data and Second Quarter 2024 Financial Results

Candel Therapeutics reported positive survival data from its CAN-2409 trials in pancreatic and lung cancer, along with second quarter financial results and key corporate updates.

Summary

• Candel Therapeutics announced its second quarter 2024 financial results and provided a corporate update, highlighting significant clinical advancements and regulatory successes.
• The company reported positive survival data from the phase 2 trial of CAN-2409 in borderline resectable pancreatic cancer, showing a median overall survival of 28.8 months compared to 12.5 months in the control group.
• In non-small cell lung cancer (NSCLC), CAN-2409 demonstrated a median overall survival of 20.6 months in patients with progressive disease despite immune checkpoint inhibitor treatment, compared to less than 12 months with standard chemotherapy.
• Candel received orphan drug designation from the FDA for both CAN-2409 for pancreatic cancer and CAN-3110 for recurrent high-grade glioma.
• The company is on track to release topline data for CAN-2409 in prostate cancer trials in Q4 2024.
• Research and development expenses were $5.0 million for the second quarter of 2024, down from $5.9 million in the same period of 2023.
• The net loss for the second quarter of 2024 was $22.2 million, compared to a net loss of $9.6 million for the second quarter of 2023, primarily due to a change in the fair value of the company's warrant liability.
• As of June 30, 2024, Candel had $21.5 million in cash and cash equivalents, which is expected to fund operations into Q1 2025.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial results and regulatory achievements, but the increased net loss and decreased cash position temper the overall sentiment. The positive clinical data is a strong driver for a positive sentiment.

Positives

• The median overall survival for pancreatic cancer patients treated with CAN-2409 was significantly higher at 28.8 months compared to 12.5 months in the control group.
• CAN-2409 showed a substantial improvement in median overall survival for NSCLC patients at 20.6 months compared to less than 12 months with standard chemotherapy.
• Orphan drug designation from the FDA for CAN-2409 and CAN-3110 provides potential market exclusivity and development incentives.
• The company is on track to release key data readouts for prostate cancer trials in Q4 2024.
• Candel's inclusion in the Russell 3000 Index increases its visibility within the investment community.
• The company's cash runway extends into Q1 2025, providing financial stability for ongoing operations.

Negatives

• The net loss for the second quarter of 2024 was $22.2 million, significantly higher than the $9.6 million loss in the same period of 2023.
• The increase in net loss was primarily due to a $13.3 million change in the fair value of the company's warrant liability.
• Cash and cash equivalents decreased from $35.4 million at the end of 2023 to $21.5 million as of June 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital or achieve profitability.
• Clinical trial results may differ from reported interim data, impacting the perceived efficacy of the company's product candidates.
• The company faces risks related to obtaining and maintaining regulatory approvals for its product candidates.
• The company's intellectual property may not be adequately protected.
• The company's business model and strategic plans may not be successfully implemented.

Future Outlook

The company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2025. Topline data from prostate cancer trials are expected in Q4 2024.

Management Comments

• The second quarter of 2024 represented a pivotal period for Candel, characterized by robust clinical advancements and key regulatory successes, that further validate our innovative approach to cancer immunotherapy, said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
• Our encouraging overall survival phase 2 data for CAN-2409 highlights the potential of our lead candidate to address a significant unmet need for non-small cell lung cancer patients, who are non-responsive to immune checkpoint inhibitor treatment, and for patients with borderline resectable pancreatic cancer.
• The FDA granting orphan drug designation for CAN-3110 in recurrent high-grade glioma underscores the promise of this first-in-class, novel asset developed for difficult-to-treat cancers.
• Our inclusion in the Russell 3000 Index also marks a significant milestone in Candel's growth and offers an opportunity to increase our recognition within the investment community.

Industry Context

Candel's focus on multimodal biological immunotherapies aligns with the growing trend in cancer treatment towards personalized and immune-based therapies. The positive data from CAN-2409 trials in pancreatic and lung cancer positions the company as a potential player in these difficult-to-treat cancers.

Comparison to Industry Standards

• The median overall survival of 28.8 months for CAN-2409 in pancreatic cancer is significantly higher than the historical median survival of around 12 months with standard of care, suggesting a potential breakthrough in this area.
• The 20.6 months median overall survival in NSCLC patients treated with CAN-2409 compares favorably to the less than 12 months typically seen with docetaxel-based chemotherapy in similar patient populations, as referenced in the Reckamp KL, et al. J Clin Oncol. 2022;40(21):2295-2306 study.
• Companies like BioNTech and Moderna have also shown success with mRNA-based cancer therapies, but Candel's approach using viral vectors offers a different mechanism of action that may be beneficial in certain patient populations.
• The orphan drug designation for both CAN-2409 and CAN-3110 is a positive sign, as it provides potential market exclusivity and development incentives, similar to other companies developing treatments for rare diseases.

Stakeholder Impact

• Shareholders may view the positive clinical data favorably, but the increased net loss and decreased cash position could raise concerns.
• Employees may be encouraged by the clinical progress and regulatory successes.
• Patients with pancreatic cancer, NSCLC, and rHGG may benefit from the potential new treatment options.
• Creditors may be concerned about the company's financial position and cash burn rate.

Next Steps

• Updated phase 1b data (Arm C) for CAN-3110 in rHGG is expected in H2 2024.
• Phase 2b topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer is expected in Q4 2024.
• Phase 3 topline disease-free survival data for CAN-2409 in localized intermediate/high-risk prostate cancer is expected in Q4 2024.

Key Dates

Keywords

Candel Therapeutics, CAN-2409, CAN-3110, Pancreatic Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Orphan Drug Designation, Immunotherapy, Clinical Trials, Financial Results